<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065440</url>
  </required_header>
  <id_info>
    <org_study_id>06-2011-65</org_study_id>
    <nct_id>NCT02065440</nct_id>
  </id_info>
  <brief_title>The Effect of Ebastine/Pseudoephedrine on Subacute Cough</brief_title>
  <official_title>The Effect of Ebastine/Pseudoephedrine on Subacute Cough :a Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether ebastine/pseudoephedrine is effective on subacute cough.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Visit 0 week

             -  Patients with subacute cough,area randomized to either ebastine/pseudoephedrine or
                placebo for 1 week.

             -  The cough severity and quality of life were measure with VAS score and
                cough-specific quality-of-life questionnaire(CQLQ)

        2. Visit 1 week check VAS score and CQLQ

        3. Visit 4 weeks check VAS score and CQLQ
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of VAS score</measure>
    <time_frame>1 week later after administration of ebastine/pseudoephedrine or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of VAS score</measure>
    <time_frame>4 weeks later after administration of ebastine/pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with more than 50 percent decrease in VAS score</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CQLQ score</measure>
    <time_frame>1week later after administration of ebastine/pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CQLQ score</measure>
    <time_frame>4 weeks later after administration of ebastine/pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Ebastine/Pseudoephedrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of ebastine/pseudoephedrine 1cap/day for 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of placebo pill 1 cap/day for 1week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhinoebastel</intervention_name>
    <description>Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.</description>
    <arm_group_label>Ebastine/Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with subacute cough(3-8 weeks)

          -  age: 20-70 years

        Exclusion Criteria:

          -  Chest X-ray abnormality(+) as a probable cause of cough

          -  other explainable confirmed diagnosis(+) such as acute infectious disease

          -  Severe cough or cough complication which needs other anti-tussive agents.

          -  on ACEI

          -  with more than three hypertensive agents

          -  change of hypertension medication 3 months ago

          -  immunocompromized host

          -  relative or absolute contraindication for ebastine/pseudoephedrine

               1. hypersensitivity to ebastine/pseudoephedrine

               2. glaucoma

               3. moderate to severe hypertensive disease

               4. coronary heart disease

               5. hyperthyroidism

               6. moderate to severe liver disease

               7. benign prostate hyperplasia

               8. psychological problem

               9. Parkinson's disease

              10. on linezolid or supposed to use it.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Hoon Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-Gu</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2014</study_first_submitted>
  <study_first_submitted_qc>February 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>February 16, 2014</last_update_submitted>
  <last_update_submitted_qc>February 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebastine/Pseudoephedrine</keyword>
  <keyword>subacute cough</keyword>
  <keyword>upper airway cough syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Ebastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

